Highest-materiality recent filing
Teladoc Health holds 2026 annual meeting; all director nominees elected
All eight director nominees elected; David B. Snow, Jr. received 67.4M for (12.9M against).
Teladoc Health Q1 2026 Revenue Falls 2% to $613.8M, Net Loss Narrows to $63.8M
First Quarter 2026 revenue of $613.8 million, down 2% year-over-year
Teladoc Health appoints Susan Salka, ex-AMN Healthcare CEO, to its board
Susan Salka appointed to Teladoc board effective March 30, 2026; will serve on audit and compensation committees.
Teladoc Q4 revenue flat at $642M, net loss narrows; FY2026 revenue guidance $2.47-2.587B
Q4 2025 revenue $642.3M (flat YoY); net loss $25.1M vs $48.4M loss; adjusted EBITDA $83.8M (+12% YoY).
Teladoc appoints Michael Smith, former Voya Financial CFO, to board
Appointment of Michael Smith to board effective Feb 18, 2026; board size temporarily expanded to 10.
Director Thomas G. McKinley to retire from Teladoc Health board effective Feb 20, 2026
Thomas G. McKinley, a director since 2009, notified Teladoc of his retirement effective Feb 20, 2026.
Teladoc director J. Eric Evans to retire at 2026 Annual Meeting, not standing for reelection
J. Eric Evans notified Teladoc on Dec 11, 2025 of intention not to stand for reelection at the 2026 Annual Meeting.
Teladoc Health increases inducement plan share reserve by 1.78M shares to 7.28M
Board approved amendment effective Dec 9, 2025 to increase share reserve by 1,780,000 shares to total 7,280,000 shares under 2023 Inducement Plan.
Teladoc Q3 revenue down 2% to $626.4M; net loss widens to $49.5M; adj. EBITDA falls 16%
Revenue $626.4M (-2% YoY); net loss $49.5M ($0.28 per share) vs. $33.3M loss a year ago.
Teladoc Health CFO Mala Murthy resigns; preliminary Q3 revenue $626.4M, adj EBITDA $69.9M
CFO Mala Murthy to resign effective Nov 21, 2025; interim finance leaders reporting to CEO.
Net loss of $32.7M ($0.19 per share), improved from $837.7M loss in Q2 2024 which included $790M goodwill impairment.
Teladoc Health enters $300M senior secured revolving credit facility
Five-year $300M senior secured revolver with JPMorgan Chase as administrative agent; no immediate borrowings planned.
Shareholders approved amendment to 2023 Incentive Award Plan, increasing authorized shares by 6,850,000.
Teladoc Q1 revenue down 3% to $629M; net loss widens on $59M goodwill impairment; acquires UpLift
Revenue $629.4M (-3% YoY); net loss $93M ($0.53/sh) includes $59.1M goodwill impairment.
Teladoc Health Q4 revenue $640.5M (-3% YoY); full-year net loss $1.0B on $790M goodwill impairment
Q4 revenue $640.5M (-3% YoY); full-year revenue $2,569.6M (-1% YoY).
Teladoc Q3 revenue $640.5M (-3% YoY), net loss narrows to $0.19 EPS; BetterHelp revenue down 10%
Revenue $640.5M (-3% YoY); net loss $33.3M ($0.19 per share) vs $57.1M loss last year.
Teladoc Health COO Michael Waters resigns effective Dec 31, 2024
COO Michael Waters resigns with good reason due to change in executive reporting structure.
Teladoc Health appoints Joseph Catapano as SVP and Chief Accounting Officer
Joseph Catapano joined Teladoc as SVP and Chief Accounting Officer effective Sept 9, 2024.
Q2 revenue $642.4M (-2% YoY); net loss $837.7M ($4.92/sh) includes $790M goodwill impairment for BetterHelp.
Teladoc Health terminates President Laizer Kornwasser without cause, effective July 1, 2024
Laizer Kornwasser, President of Enterprise Growth and Global Markets, terminated without cause; effective July 1, 2024.
Teladoc Health names Chuck Divita as CEO effective June 10, 2024
Charles Divita appointed CEO and board member; Mala Murthy returns to CFO role.
Teladoc Health reports 2024 annual meeting voting; all director nominees elected
All eight director nominees elected; votes for ranged from 74.9M to 88.2M.
Teladoc Health Q1 revenue +3% to $646.1M; adjusted EBITDA +20% to $63.1M
Revenue $646.1M (+3% YoY); net loss $81.9M ($0.49 EPS) vs $69.2M loss in Q1 2023.
On September 27, 2024, Michael Waters, Chief Operating Officer of Teladoc Health, Inc. (the “Company”), resigned with good reason under his executive employment agreement with the Company in connection with a change in the Company's executive reporting structure.
Effective September 9, 2024, Joseph Catapano joined Teladoc Health, Inc. (the “Company”) as its Senior Vice President and Chief Accounting Officer.
On June 28, 2024, Teladoc Health, Inc. (the “Company”) terminated without cause the employment of Laizer Kornwasser, President, Enterprise Growth and Global Markets, in connection with a change in the Company's executive reporting structure, effective July 1, 2024.
appointed Mr. Divita as a director of the Company.
Charles Divita, III joined Teladoc Health, Inc. (the “Company”) as its Chief Executive Officer.
Mala Murthy stepped down as acting Chief Executive Officer of the Company and will remain the Company's Chief Financial Officer.
Max materiality 0.85 · Median 0.55 · Most common event earnings